印度公司Shilpa Medicare Ltd完成了对重组人体白蛋白20%的第一阶段试验. Indian firm Shilpa Medicare Ltd completes Phase 1 trial for recombinant human albumin 20%.

印度制药公司Shilpa Medicare Ltd成为该国首家成功完成其重组人体白蛋白 (rHA) 20%的第一阶段临床试验的公司. Indian pharmaceutical firm Shilpa Medicare Ltd becomes the first in the country to successfully complete Phase 1 clinical trial for its recombinant human albumin (rHA) 20%. 该试验涉及62名健康志愿者,该产品旨在作为血浆衍生人体血清蛋白的可行替代品,而血浆衍生血清蛋白对各种医疗治疗至关重要。 The trial involved 62 healthy volunteers, and the product aims to serve as a viable alternative to plasma-derived human serum albumin, which is essential for various medical treatments. 该公司计划在第4个财政年度25之前启动第3阶段试验。 The company plans to initiate Phase 3 trials by Q4 FY25.